STOCK TITAN

Rubric Capital discloses 6.75% Arcutis Biotherapeutics (ARQT) ownership stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Rubric Capital Management and David Rosen report passive ownership of 6.75% of Arcutis Biotherapeutics, Inc. common stock on an amended Schedule 13G. They beneficially own 8,271,577 shares with shared voting and dispositive power and no sole authority.

The ownership percentage is based on 122,492,192 shares outstanding as of October 22, 2025, as disclosed in Arcutis’s Form 10-Q for the quarter ended September 30, 2025. The filers certify the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Rubric Capital Management LP
Signature:/s/ Michael Nachmani
Name/Title:Michael Nachmani / Chief Operating Officer
Date:02/13/2026
David Rosen
Signature:/s/ David Rosen
Name/Title:David Rosen / Individually
Date:02/13/2026

FAQ

What ownership stake in ARQT does Rubric Capital report on this Schedule 13G/A?

Rubric Capital and David Rosen report beneficial ownership of 8,271,577 Arcutis Biotherapeutics shares, representing 6.75% of the common stock. All voting and dispositive power over these shares is shared, with no sole authority reported by either filing person.

How many Arcutis (ARQT) shares were used to calculate the 6.75% stake?

The 6.75% ownership stake is based on 122,492,192 Arcutis common shares outstanding as of October 22, 2025. That share count comes from the company’s Form 10-Q for the quarter ended September 30, 2025 filed with the SEC.

Is Rubric Capital’s stake in Arcutis (ARQT) reported as passive or active?

The stake is reported as passive. The filers certify the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Arcutis, consistent with a Schedule 13G filing standard.

Who are the reporting persons on this Arcutis (ARQT) Schedule 13G/A?

The reporting persons are Rubric Capital Management LP and David Rosen. Rubric Capital is the investment adviser to the funds holding Arcutis shares, and Rosen is the Managing Member of Rubric Capital Management GP LLC, Rubric Capital’s general partner.

What voting and dispositive powers over ARQT shares do the filers report?

Both Rubric Capital and David Rosen report zero sole voting and sole dispositive power. They each report shared voting power over 8,271,577 shares and shared dispositive power over the same amount, reflecting joint authority regarding these Arcutis holdings.

Which Rubric fund has rights to more than 5% of Arcutis (ARQT) stock?

Rubric Capital Master Fund LP, one of the Rubric Funds, has the right to receive or direct the receipt of dividends or sale proceeds from more than 5% of Arcutis’s common stock, according to the ownership disclosure and related explanation in the filing.
Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

ARQT Rankings

ARQT Latest News

ARQT Latest SEC Filings

ARQT Stock Data

3.17B
110.47M
1.9%
109.89%
14.19%
Biotechnology
Pharmaceutical Preparations
Link
United States
WESTLAKE VILLAGE